A new drug to protect the vulnerable against Covid has the potential to save hundreds of thousands of patients with weaker immune systems, but is yet to be funded by the Government.
Evusheld, made by AstraZeneca in the UK, is being used by millions in 32 countries around the world.
It offers advanced protection for people having cancer treatment, organ transplant recipients, primary immuno-deficiency patients and arthritis sufferers.
